Skip to main content

Alimta FDA Approval History

FDA Approved: Yes (First approved February 4, 2004)
Brand name: Alimta
Generic name: pemetrexed
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer

Alimta (pemetrexed) is an antifolate antineoplastic agent indicated for the treatment of malignant pleural mesothelioma and locally-advanced and metastatic non-small cell lung cancer (NSCLC).

Development timeline for Alimta

DateArticle
Jul  7, 2009Approval Lilly Receives Fourth FDA Approval for Alimta (pemetrexed for injection) as Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer
Sep 29, 2008Approval FDA Grants Lilly's Alimta (Pemetrexed for Injection) Third U.S. Approval
Feb  4, 2004FDA Approves Alimta for use with cisplatin, for the treatment of Malignant Pleural Mesothelioma
Feb  4, 2004Approval FDA Approves Alimta for Malignant Pleural Mesothelioma

See also

Alimta (pemetrexed) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer